Member Info for RichKen

I managed to acquire another £10k this morning. At anything under £1.30 it is at this time crazy not to with available funds.
Looking forward to the multiple news updates coming our way in the weeks ahead. I am very confident in my consistent buying here.
Cheers RK

Due to business commitments, I was only able to listen to part of today's presentation, so I do not have all aspects available to be that I wanted to have today, but I picked up enough and understand enough from recent reports and the global situation to know that whatever the short term movement the long term growth is going to be very strong.

A general observation - global markets over the last 3 weeks have rallied to a point which has been unsustainable given the continued spread of the virus. Many people countries in the world including our own are not taking the right precautions and are becoming risk to themselves and to others and without treatments and full testing the world is going to head into a huge recession. The UK and many parts of the world have many cancer treatments and surgery for serious illness on hold and this is going to create huge anxiety going forward if action cannot be taken and solutions are not in place. This is a global situation and much worse in other countries but we are not far behind.

This brings us back to Avacta. So the prototype LFD will be ready within 2 weeks (end of June) ready for testing and validation. The BAMS which is likely to take a large share of the PCR market is going out for testing and validation and will be ready soon.
The global market as we have discussed on this board every week for weeks is huge (people may think it is going away - but actually it is increasing). The company is investing heavily to increase its ability to produce the Affimers for the testing production-ready for the up and coming demand.

Then we look at the pre|CISION targeted Chemotherapy treatments. It looks like the extra money which has come from the placing is going to be used to accelerate the development and trials. If human trials show as much promise as the lab tests this will have a huge take-up and given the combination of backlogs from the COVID19 situation people are going to be queueing up to try take this new powerful treatment. We can be sure that multiple pharmaceutical companies are going to want this technology in there control.

But in the meantime, there is a strong possibility we will have a joint listing on the Nasdaq, bringing in a another large chunk of money to the business to accelerate development further. A US listing for a company with such huge upside is going to be like a magnet to investors. I am sure though that listing will lead to an offer within months of that listing.

The number if income streams here is off the scale. I think Alastair Smith could have talked for 3 or more hours and given us much more. But the stream of news in the pipeline will lead to many RNS's over the weeks and years ahead which are going to keep investors excited.

I am not selling anytime soon and I intend to continue to build my holdings and I see in the days ahead this is going to be a good place to have a large percentage of my investment portfolio.

Cheers, RK

Olderandwiser, yes sorry I was typing on the un trusty iPAD - ‘analogy’ was my word selection. When is ‘Apple‘ going get its word prediction correct. My secretary keeps up with me, but not Siri!
Thanks RK

It is spelt A V A C T A ! !

Oh I am looking for £5 Billion as a market cap.

Thanks :-))

....Oh yes, it is...!
There is no doubt having this evening an RNS with this small but valuable Hedge Fund from the US on the investor's list is going to be a valuable underlining to this company and the building sentiment around the upside of the Affimner technology. The more we research and see the news unfolding here of what this technology can do it becomes clearer that this is like a 'super magnet' for proteins which with tiny changes to the chemistry using simple structure change can attract almost anything they want in the body, virus proteins, tumour traces and most likely anything.

It has been stated that Affimers to the body is like the software to a PC. If this turns out to be a perfect anomaly then we are going to see a lot more seriously ambitious investors coming on board. These people are seriously influential and we have what may turn out to be the most important step-change in treatment and diagnosis that medicine has ever seen.

I wonder how many more of these big players are going to come on board. Tonights RNS will be looked at by quite a few serious fund managers.

I think I am getting a little excited!

Time to stop! Have a good evening all!

Cheers, RK

Anyone who pays money to get advice from TW is a fool in my perspective. He tips shares and ramps them, then shorts them to death! There are few pwople I have ever meet in the investing world who is pleased with their performance profits of doom if you ask me.
Motley Fool have tipped some good companies in the past with good results. Boohoo was one of theirs, Burford Capital, Gear4Music, Burberry, BluePrism, Keywords Studios. All of those have done very well indeed. Nobody gets every tip right. But the TW crew have no morals and not many fans from peoples experaince that has been shared to me. I have never subscribed or followed any of there people or tips and I have no intention to do so. They probably have a spread bet on Avacta to fall to less than £1. Assuming the tests are a flop. But they probably have no idea about the other huge opportunities for Affimers.
Any investors with a view to holding here over 12 to 24 months are likely to incredible returns on their investments.
My own opinions only. But don't follow the TW team. They want to spell doom and gloom so they can cash in on their spread bet!
Cheers, RK

Chengdo4, this is certainly going to become a very competitive market, but we should have a cost and speed advantage on both tests as well as specific accuracy to match or beat any competitor. But we will see.

The one thing is looking certain that this presentation next week would not be happening if we did not have a successful LFT ready for market. Companies don't show off their faults they present their successes!

So we are looking good.

Cheers, RK

At any one time, people look at the available options and the prices.

Once the BAMS and LFT are available our market share will increase from zero to within the a margin of the top devices available as we will have a cost advantage as well as a diagnostic advantage in every case. I truly think that Avacta will only be held back by what they can produce for 6 to 12 months and orders once they start coming in will exceed any expectations.

But Avacta are doing everything they can to be ready.

Decided to add another £4K on the dip today. At current levels, I don't think you can have enough of these shares!

But my focus is on 2021 when the pre|CISION and the various chemotherapy solutions as this is where the incredible long term value prospect will come from!

Cheers, RK

Traz, Have a look at this. It will help you as a newbie!
https://avacta.com/how-a-lateral-flow-rapid-test-works/
Cheers, RK

The Lateral Flow Test doesn’t need Clinical Trials.
They only need to test sensitivity and selectivity against the known data.
Hope that gives you some assurance.
Cheers RK

I suggest researching the list of chemotherapy treatments on page 14 of the report. If we are able to develop pre|CISION for all these and reduce or eliminate the cancer tumours in all cases this will be a great comfort to anybody be with cancer.

https://avacta.com/wp-content/uploads/2020/06/Placing-Presentation-June-2020.pdf

These are the real reasons that you are invested here!
Cheers RK

Good morning everyone,
I think if people want something to read look at the progress the company is hoping to make with Developement of cancer therapeutics in 2020!
This report will give you strength me encouragement!
https://avacta.com/wp-content/uploads/2020/06/Placing-Presentation-June-2020.pdf
Cheers RK

AntiFragile, SMT is another very good growth Trust Fund. This has an advantage you can buy and sell like a normal stock. It is possible to trade this through markets volatility but it doesn’t always go where people think. Best Buy and forget. There are some common stocks in SMT to Fundsmith.
Good call.
Cheers RK

Because people are generally complacent the Covid19 virus has little chance of being eradicated by the public without a cure. People start off well like they do when they decide on a new years resolution then it all fades away. I'll be alright, and then the invisible enemy strikes!
So anyone who thinks Covid19 is over better think again.
If you go out take the right precautions and remember the advice! It is your life and your family.
This means Avacta's test will be very useful very soon!
Cheers, RK

Hi Adam,
Firstly I cannot give you or anyone else financial advice. I can share thoughts and ideas but they are just that. What I am going to say is not meant to harsh or degrading but it is a reality in many new investors.
It is too late now in some respects because it sounds like you like a flutter and you are following a whim rather than understanding the market that your investment is in. If you use past trends to invest that does not always work in your favour. Take an oil investment for example. Oil has been and could still be an important part of life, fuel, plastics, as well as buy products. But, the world is looking away from fossil fuels and everyman and his oil well have a prospect that could be worth billions (UKOG for example), but the reality is the market is dominated by huge players. The question is do you know the oil industry inside out or have you been tipped by a mate? Unless you know the market, very risky! A possible future is Hydrogen. Emerging and huge upside! But dont just buy the first stock learn for a few weeks then make a decision!
Avacta, well we are all experts here arent we? Or are we? We understand the need for testing, we understand the need for treatments. Avacta has a solution and it looks great. The Affimer technology is a revolution and it is completely binary in that it works in the lab it is clear. Its technology looks to have huge potential a market disrupter. Investors here have hung the coats on it. But are you a scientist? Do you really know it are you an expert in what makes this Biotech company the best? Momentum in a company and huge followings will draw investors in. Infact many investments are like Affimers they attract investors in swarms because it is 'the one'.
As a private investor you need to read, research, work out the risk, decide on an exit point and consider what happens if it fails or doesn't make it because something else comes along. We have seen plenty of that in the COVID stocks, expectation, delivering, production - oh! Look that one is even better! If you time this perfectly you can make a fortune because you are reading them all and know what to look for!
But, you work, you are just reading snippets, you follow sentiment?
So the best advice is if you don't know what you are doing, leave it to someone who does, a solid investment fund, well managed and consistent, lower risk and constant returns. You will have the odds stacked in your favour, but there is still a risk. Find 4 or 5 and spread your risk. I will not give you a list of them but have a look. I will give you just one Fundsmith. Look at the history and which companies are in the portfolio. Even when the market crashes they still went down, but they recovered, no one is perfect!
Don't ever risk what you cannot afford to lose especially in a pension. It is your future.
I am not sure this is the answer you wanted. No investor is perfect. Not even Warren Buffet!
Cheers, RK

How long do you think it will take to develop the test?

These types of BAMS tests are really quite quick to develop so we think a few weeks with the reagents that we supplied to Adeptrix and then, of course, the test will need to be clinically validated as all new tests are but again, that should only take a few weeks.
The approvals process should be fairly rapid and we expect to have an approved test for use, if all goes well, early in the summer.

When the test is working, what’s the route to market?

The test will take the form of a kit of reagents, including the Avacta Group Affimer reagents, and it’s that kit that will be sold to hospitals and other laboratories for the use on the mass spectrometer. The manufacturers of these mass spectrometers, like Shimadzu, Bruker, Waters, Agilent, they are the best route to market to supply the kits to run on their installed base of machines.
So, we’re already in discussions with some of those parties to get test commercialised and into use as quick as possible.

There is an RNS awaiting to come and that will be soon - distribution partners for the BAMS test reagents! That really is due soon!

Cheers, RK

Weloil, I think every investor here will be delighted to read than RNS when it comes.

But we know that it may well not come till the end of the month and that is based on a real time frame. But other news may well arrive ahead of this or the need is so great that Adeptrix and Cytiva pull Avacta Affimer rabits out of the hat and we are there faster.
I am sure that Affimer technology is going to be huge and our time is coming. Most investors have only been here for 6 to 8 weeks. Avacta started with Alastair Smith in June 2005. 15 years and he is still pushing forward!
We have to wait 3 to 4 weeks? It really is not very long. In 12 months our SP will likely be many multiples of today's price.
We could all sell up and invest in something else and miss the boat and worse buy something which is not going to have anything like the potential here.

The other underlying point is today the global markets have had a recovery based on a sentiment of hope. That sentiment is likely to take a major bash because of the potentially imminent second wave and the drop of global markets is likely to be huge. However, sitting on a company which holds the keys to diagnosing and stopping it might just prove to be the most prudent investment ever!

Just my thoughts..

Cheers, RK

1. Astra Zenica - why great portfolio and a British company! Negative, they might not offer enough!
2. Roche - A perfect fit for the future and cash-rich
3. Danaher - They are already a partner by Cytiva but they may want to take a much larger stake
4. GSK - Possible but unlikely

Interested in other suggestions and why?

Cheers, RK

...very straight, Jokickass, Alastair Smith is sure the tests will work. he has said it is just a case of going through the process. Affimer technology is like a magnet. The Affimer carries the magic protein and it latches on to the virus in an instant.
I am 100% sure this will work and I am 100% sure that the BAMS and LFT will become the gold standard in testing across the planet.
I am sure that Avacta will find the right partner to develop the virus blocker using Afmers too and that will lead to an acceleration in the development of the pre|CISION cancer treatment to market which will lead to this company having a multi-Billion pound valuation!
I will be here until they do! These processes take time and the due diligence process for validation and certification takes a miniumum of 8 weeks for BAMS and LFT.

We just have to wait. I don't think we can find more pointers of confidence than have been given!

Cheers, RK

I think following on from our comments on PCR SiriusB, that the BAMS testing with Adeptrix very much could replace PCR. I would expect it to be faster and much much cheaper. If the distribution by Adeptrix could also be sorted quickly this could help faster and lower-cost testing in hospitals and health centres around the world.

Avacta covers both bases for 'instant' testing with Point of Care and in the Lab.

BAMS testing is going to come first.

Cheers, RK